Neutrophil:lymphocyte ratio predicts short-term outcome of COVID-19 in haemodialysis patients

Mutinelli-Szymanski, Prisca; Hude, Iulia; Merle, Emilie; Lombardi, Yannis; Seris, Pascal; Abtahi, Medhi; Azeroual, Latifa; Bourgain, Cecile; Ensergueix, Gael; Katerinis, Ioannis; Kolko, Anne; Kolta, Amir; Maheas, Catherine; Mehrbanian, Saeed; Morel, Pauline; Ossman, Rim; de Préneuf, Hélène; Roux, Arthur; Saltiel, Claudine; Vendé, Florence; Verhoeven, Anne-Sophie; Viron, Béatrice; Laplanche, Sophie; Le Monnier, Alban; Ridel, Christophe; Ureña-Torres, Pablo; Touzot, Maxime

BACKGROUND: Information regarding coronavirus disease 2019 (COVID-19) in haemodialysis (HD) patients is limited and early studies suggest a poor outcome. We aimed to identify clinical and biological markers associated with severe forms of COVID-19 in HD patients. METHODS: We conducted a prospective, observational and multicentric study. Sixty-two consecutive adult HD patients with confirmed COVID-19 from four dialysis facilities in Paris, France, from 19 March to 19 May 2020 were included. Blood tests were performed before diagnosis and at Days 7 and 14 after diagnosis. Severe forms of COVID-19 were defined as requiring oxygen therapy, admission in an intensive care unit or death. Cox regression models were used to compute adjusted hazard ratios (aHRs). Kaplan–Meier curves and log-rank tests were used for survival analysis. RESULTS: Twenty-eight patients (45%) displayed severe forms of COVID-19. Compared with non-severe forms, these patients had more fever (93% versus 56%, P < 0.01), cough (71% versus 38%, P = 0.02) and dyspnoea (43% versus 6%, P < 0.01) at diagnosis. At Day 7 post-diagnosis, neutrophil counts, neutrophil:lymphocyte (N:L) ratio, C-reactive protein, ferritin, fibrinogen and lactate dehydrogenase levels were significantly higher in severe COVID-19 patients. Multivariate analysis revealed an N:L ratio >3.7 was the major marker associated with severe forms, with an aHR of 4.28 (95% confidence interval 1.52–12.0; P = 0.006). After a median follow-up time of 48 days (range 27–61), six patients with severe forms died (10%). CONCLUSIONS: HD patients are at increased risk of severe forms of COVID-19. An elevated N:L ratio at Day 7 was highly associated with the severe forms. Assessing the N:L ratio could inform clinicians for early treatment decisions.